TABLE 1.
Registered clinical trials on https://clinicaltrials.gov focused on microglia and multiple sclerosis.
| NCT number | Title | Status | Conditions | Study type | Interventions | Phase | Study completion date |
| NCT04925557 | Study to Assess the Efficacy of Mayzent on Microglia in Secondary Progressive Multiple Sclerosis | Not yet recruiting | Secondary progressive multiple sclerosis | Interventional | ∙ Drug: Mayzent ∙ Drug: Ocrevus | 4 | April 30, 2025 (estimated) |
| NCT03368677 | Effect of Teriflunomide Treatment on Microglial Activation in an MS Patient Cohort at Risk of Progression (TERIPET) | Recruiting | Multiple sclerosis | Observational | – | Not applicable | November 2024 (estimated) |
| NCT04239820 | Effect of Cladribine Treatment on Microglial Activation in the CNS (CLADPET) | Recruiting | Multiple sclerosis | Observational | ∙ Radiation: Imaging | Not applicable | June 2024 (estimated) |
| NCT04126772 | Multimodal Imaging of MS Reveals the Smoldering Inflammation (PLAQ-MS) | Recruiting | Multiple sclerosis | Observational | – | Not applicable | September 2023 (estimated) |
| NCT03134716 | Role of Microglia in the Pathogenesis of Progressive Multiple Sclerosis (PROMS) | Active, not recruiting | Multiple sclerosis | Observational | – | Not applicable | April 2023 (estimated) |
| NCT03691077 | Effect of Ocrelizumab on Brain Innate Immune Microglial Cells Activation in MS Using PET-MRI With 18F-DPA714 (INN-MS) | Recruiting | Multiple sclerosis Relapse Primary progressive multiple sclerosis | Interventional | ∙ Drug: Ocrelizumab | 3 | September 2022 (estimated) |
| NCT04230174 | Effect of Ocrelizumab on Neuroinflammation in Multiple Sclerosis as Measured by 11C-PBR28 MR-PET Imaging of Microglia Activation | Not yet recruiting | Multiple sclerosis | Interventional | ∙ Drug: 11C-PBR28 | 4 | July 2022 (estimated) |
| NCT04546698 | 5-HT7 Receptor Implication in Inflammatory Mechanisms in Multiple Sclerosis (5-HTSEP) | Recruiting | Multiple sclerosis Acute relapsing multiple sclerosis | Observational | ∙ Other: Blood sampling | Not applicable | March 2022 (estimated) |
| NCT04510220 | 9-Month Study to Assess the Efficacy of Ofatumumab on Microglia in Patients With Relapsing Forms of Multiple Sclerosis | Recruiting | Relapsing multiple sclerosis | Interventional | ∙ Drug: Ofatumumab ∙ Drug: [F-18]PBR06 | 3 | December 31, 2021 (estimated) |
| NCT03759522 | Assessment of Neuroinflammation in Central Inflammatory Disorders Using [F-18]DPA-714 (DPA-714) | Recruiting | Fibromyalgia Chronic fatigue syndrome Multiple sclerosis | Interventional | ∙ Drug: DPA-714 PET/MRI | 1 | November 1, 2021 (estimated) |
| NCT02207075 | Measuring Active Microglia in Progressive Multiple Sclerosis | Active, not recruiting | Secondary progressive multiple sclerosis | Observational | ∙ Drug: [C11]PK-1195 PET scan | Not applicable | December 2020 (estimated) |
| NCT02446886 | Adrenocorticotropic Hormone (ACTH) Effects on Myelination in Subjects With MS | Terminated | Multiple sclerosis | Interventional | ∙ Drug: Adrenocorticotropic hormone (ACTH) gel (H.P. Acthar)® | 4 | June 2020 |
| NCT03193086 | The Effect of Alemtuzumab on the Blood-Brain-Barrier and the Brain’s Metabolism in Multiple Sclerosis Patients | Unknown | Multiple sclerosis | Observational | ∙ Drug: Alemtuzumab | Not applicable | March 31, 2020 (estimated) |
| NCT02305264 | Imaging of Intracerebral Inflammation in MS (INFLASEP) | Unknown | Relapsing-remitting multiple sclerosis Secondary progressive multiple sclerosis Primary progressive multiple sclerosis | Interventional | ∙ Drug: 18F-DPA-714 and 18F-FDG | Not applicable | February 2018 |
| NCT01517282 | Phase Ib Study to Evaluate MOR103 in Multiple Sclerosis | Completed | Multiple sclerosis | Interventional | ∙ Biological: MOR103 ∙ Other: Placebo | 1 - 2 | February 2014 |
| NCT00861172 | Longitudinal (Weekly) Follow-Up of Active Plaques in Multiple Sclerosis With 3 Teslas Multi-Modality MRI Using Diffusion, Perfusion, Venography and Proton Spectroscopy (IRM 3T-SEP) | Completed | Lesions Multiple sclerosis | Interventional | ∙ Procedure: 3T MR scanner | Not applicable | July 2012 |